Skip to content

Lifecore Biomedical, Inc. LFCR Change in receivables

Change in receivables at other companies

Medpace Holdings, Inc. logo
Medpace Holdings, Inc.MEDP
-$7.82M-478%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$474K-96.6%

Other financials

Income statement

See full
Revenue$23.2M-36.4%
Gross profit$4.5M-68.1%
Operating income-$4.7M
Net income-$15.0M-1,206%
EPS (diluted)-$0.43-1,333%

Balance sheet

See full
Cash & equivalents$20.8M+152%
Total debt$156.9M+1,310%
Total equity-$28.4M-2,229%
Total assets$225.5M-5.8%

Cash flow

See full
Operating cash flow$4.7M
CapEx$1.1M-46.7%
Free cash flow$3.6M

Valuation

See full
Market cap$196.92M-35.4%
Enterprise value$333.06M+8.3%
P/S1.6×+0.5×

Profitability

See full
Gross margin31.3%-1.4pp
Operating margin-14.5%-2.2pp
Net margin-30%
FCF margin-36.4%

Returns & leverage

See full
Return on equity-612.1%
Debt / equity8.3×-1.5×
Current ratio3.8×+0.9×

Where this comes from

Reported directly by Lifecore Biomedical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInReceivables.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s change in receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s change in receivables?
Lifecore Biomedical, Inc. (LFCR) reported change in receivables of -$6.77M in Q1 2026.
How has Lifecore Biomedical, Inc.'s change in receivables changed year-over-year?
Lifecore Biomedical, Inc.'s change in receivables decreased by 507.9% year-over-year, from $1.66M to -$6.77M.
What does change in receivables mean?
Change in total receivables including trade and non-trade receivables.